Stock MRK MERCK & CO., INC.
Add to a list

Merck & Co., Inc. Share Price

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 21:00:56 05/06/2026 BST 		After hours 23:00:05
120.79 USD +0.44% Intraday chart for Merck & Co., Inc. 120.28 -0.42%
06-04 Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases MT
06-04 Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases, Bloomberg Reports MT

Valuation: Merck & Co., Inc.

Capitalization 297B 258B 236B 223B 414B 28,198B 422B 2,810B 1,093B 13,675B 1,115B 1,091B 47,610B P/E ratio 2026 *
53.7x
P/E ratio 2027 * 14.5x
Enterprise value 333B 289B 265B 250B 465B 31,651B 473B 3,154B 1,227B 15,350B 1,252B 1,225B 53,442B EV / Sales 2026 *
4.99x
EV / Sales 2027 * 4.56x
Free-Float
69%
Yield 2026 *
2.78%
Yield 2027 * 2.88%
* Estimated data More valuation ratios

Chart: Merck & Co., Inc.

Dynamic Chart

Latest news : Merck & Co., Inc.

06-04 Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases MT
06-04 Merck to Pay Over $50 Million to Settle More Than 200 Gardasil Cases, Bloomberg Reports MT
06-04 Merck & Co., Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-04-2026 10:30 AM
06-04 What Bundibugyo Ebola vaccines and treatments are under development RE
06-03 HEALTH ROUNDS-Radiation-emitting implant improves outcomes after brain cancer surgery RE
06-02 Agilent Gets US FDA Clearance for Expanded Use of Cancer Test on Dako Omnis Platform MT
06-02 Merck & Co., Inc. - Special Call
06-01 Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's RE
05-31 Akeso lung cancer drug helps patients live 15% longer than immunotherapy in China trial (May 31) RE
05-29 Merck & Co., Inc. Grants Breakthrough Therapy Designation For Calderasib MK-1084 For First-Line Treatment Of Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C-Mutation CI
05-29 Merck Gets FDA Breakthrough Designation for Calderasib in NSCLC DJ
05-29 Merck's Investigational Non-Small Cell Lung Cancer Therapy Granted US FDA Breakthrough Therapy Designation MT
05-28 Declaration of Voting Results by Merck & Co., Inc. CI
More news

Last Transcript: Merck & Co., Inc.

Logo Merck & Co., Inc.
Merck & Co., Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-04-2026 10:30 AM
06-04
More transcripts

Analysts' recommendations: Merck & Co., Inc.

05-18 Regeneron drops after skin cancer treatment fails late-stage trial RE
05-01 Goldman Sachs Adjusts Merck Price Target to $137 From $133 MT
05-01 Wells Fargo Adjusts Merck Price Target to $145 From $150 MT
05-01 Morgan Stanley Raises Price Target on Merck to $112 From $109, Keeps Equalweight Rating MT
04-21 Arcus Biosciences Has Favorable Setup After Merck Belzutifan Failure, Wedbush Says MT
More recommendations

Press Releases: Merck & Co., Inc.

06-02 Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference BU
06-01 Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting AQ
05-29 FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) BU
05-28 Merck Congratulates Ontario Government on Expanding Pharmacy Scope to Help Improve Access to Care AQ
05-28 Merck to Participate in the Jefferies Global Healthcare Conference BU
More press releases

News in other languages: Merck & Co., Inc.

06-04 MÄRKTE USA/Uneinheitlich - Gewinnmitnahmen im Technologiesektor
06-04 MÄRKTE USA/Uneinheitlich - Gewinnmitnahmen im Technologiesektor
06-03 Avis d'analystes du jour : Richemont, ST et Publicis entourées
06-03 Morning Meeting: Europa will im Technologierennen wieder aufholen
06-03 L'Europe veut revenir dans la course technologique
More news

Trading Merck & Co., Inc.

Daily price chart °13611
MERCK & CO., INC.

A new test of the support level

03-19 BUY

Quotes and Performance

1 day+0.44%
1 week+0.75%
Current month+1.74%
1 month+6.79%
3 months+0.42%
6 months+19.72%
Current year+14.75%
More quotes

Course Extremes

1 week 114.36
Extreme 114.36
 123.46
1 month 110.94
Extreme 110.94
 123.46
Current year 104.43
Extreme 104.43
 125.14
1 year 76.66
Extreme 76.66
 125.14
3 years 73.31
Extreme 73.31
 134.63
5 years 70.89
Extreme 70.89
 134.63
10 years 52.83
Extreme 52.83
 134.63
More quotes

Managers and Directors: Merck & Co., Inc.

Manager TitleAgeSince
Robert Davis CEO
 Chief Executive Officer 59 30/06/2021
Caroline Litchfield DFI
 Director of Finance/CFO 57 31/03/2021
Marjorie Green CTO
 Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Tom Glocer BRD
 Director/Board Member 65 26/11/2007
Patricia Russo BRD
 Director/Board Member 73 31/08/1995
Robert Davis CHM
 Chairman 59 30/11/2022
More insiders

Latest insider transactions

Date Insider Type Main position Quantity % Market Cap.
05-28
Surendralal Karsanbhai
Other

Director

1,853 0.0001%
05-28
Kathy Warden
Other

Director

1,853 0.0001%
05-28
Inge Thulin
Other

Director

1,853 0.0001%
Transaction History

Specialty & Advanced Pharmaceuticals

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
MERCK & CO., INC. Stock Merck & Co., Inc.
+0.44%+0.75%+54.32%+7.35% 297B
MERCK KGAA Stock Merck KGaA
-1.90%+5.31%+17.67%-18.10% 70.51B
HALOZYME THERAPEUTICS, INC. Stock Halozyme Therapeutics, Inc.
-0.10%+4.91%+32.83%+113.08% 8.49B
KYOWA KIRIN CO., LTD. Stock Kyowa Kirin Co., Ltd.
-0.46%-7.01%-3.92%-16.58% 7.52B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-2.65%-5.78%-1.78%+17.00% 4.63B
YUHAN CORPORATION Stock Yuhan Corporation
-3.25%-7.30%-24.76%+33.18% 3.9B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
+1.66%+0.43%-20.88%-13.38% 2.99B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+0.11%-4.48%+38.54%+33.46% 2.59B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+0.71%-6.36%-4.53%-19.64% 1.94B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+1.01%-0.99%-17.65%-24.52% 1.76B
Average -0.44%-2.18%+6.98%+11.19% 40.13B
Weighted average by Cap. -0.06%+1.30%+43.66%+4.77%
See all sector performances

Financials

2026 *2027 *
Net sales 66.85B 58.04B 53.22B 50.11B 93.17B 6,346B 94.89B 632B 246B 3,078B 251B 246B 10,715B 70.15B 60.91B 55.86B 52.59B 97.77B 6,660B 99.58B 664B 258B 3,230B 263B 258B 11,245B
Net income 5.56B 4.82B 4.42B 4.17B 7.74B 527B 7.89B 52.56B 20.44B 256B 20.86B 20.41B 891B 20.43B 17.73B 16.26B 15.31B 28.47B 1,939B 28.99B 193B 75.15B 940B 76.69B 75.02B 3,274B
Net Debt 36.38B 31.59B 28.97B 27.27B 50.7B 3,454B 51.64B 344B 134B 1,675B 137B 134B 5,831B 23.18B 20.13B 18.45B 17.38B 32.3B 2,200B 32.9B 219B 85.28B 1,067B 87.02B 85.13B 3,715B
* Estimated data More financial data

Company Profile

Logo Merck & Co., Inc.
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (73.9%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (15.5%); - sale of animal health products (9.8%); - other (0.8%). Net sales are distributed geographically as follows: the United States (56.2%), Europe/Middle East/Africa (22.4%), Latin America (5.2%), Asia/Pacific (4.6%), Japan (4.2%), China (3%) and other (4.4%).
Employees
74,000
Sector
Pharmaceuticals
Calendar
06-15 - Ex-dividend date - 0.85 USD
More about the company

Quotes

Date Price Change Volume
05/06/26 120.79 $ +0.44% 14,362,517
04/06/26 120.26 $ +4.85% 15,933,945
03/06/26 114.70 $ -0.82% 8,225,149
02/06/26 115.65 $ +0.42% 8,311,471
01/06/26 115.17 $ -2.99% 9,406,727

Delayed Quote Nyse

More quotes

Income Statement and Estimates

More financial data

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

A
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
120.79USD
Average target price
129.74USD
Spread / Average Target
+7.41%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. MRK Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition